Despite continued concerns over terrorism and shenanigans by corporate executives that have sent the stock markets tumbling, there is some good news for dermatologists from Washington this summer. By the end of this session of Congress, there is a good chance that last year's Medicare fee cuts will be fixed and that Medicare patients will be given some form of prescription drug coverage.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.